A study including 33 pubertal males (aged 7–17 years at diagnosis) with a range of malignancies demonstrated a significant increase in basal FSH and LH when compared with healthy age-matched controls, indicating impaired spermatogenesis in the cancer survivor group. The gene discussed is BRD2; the disease is cancer.